LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Vertex Pharmaceuticals Inc

Cerrado

SectorSalud

450.57 1.61

Resumen

Variación precio

24h

Actual

Mínimo

448.53

Máximo

451.09

Métricas clave

By Trading Economics

Ingresos

-267M

646M

Ventas

-142M

2.8B

P/B

Media del Sector

30.42

51.198

BPA

4.06

Margen de beneficio

23.33

Empleados

6,100

EBITDA

-404M

782M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+14.74% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-5.4B

114B

Apertura anterior

448.96

Cierre anterior

450.57

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

120 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 may 2025, 21:00 UTC

Ganancias

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

10 feb 2025, 22:11 UTC

Ganancias

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 ene 2025, 00:19 UTC

Principales Movimientos del Mercado

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 dic 2024, 12:25 UTC

Principales Movimientos del Mercado

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 nov 2024, 21:44 UTC

Ganancias

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

6 may 2025, 16:31 UTC

Ganancias

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

5 may 2025, 20:03 UTC

Ganancias

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

5 may 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

5 may 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

5 may 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

5 may 2025, 20:01 UTC

Ganancias

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

27 abr 2025, 11:00 UTC

Principales Noticias

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

11 abr 2025, 09:30 UTC

Principales Noticias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 21:12 UTC

Ganancias

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 feb 2025, 14:21 UTC

Ganancias

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 feb 2025, 21:12 UTC

Ganancias

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 feb 2025, 21:12 UTC

Ganancias

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 feb 2025, 21:11 UTC

Ganancias

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 feb 2025, 21:04 UTC

Ganancias

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 feb 2025, 21:04 UTC

Ganancias

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 feb 2025, 21:02 UTC

Ganancias

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 feb 2025, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 feb 2025, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 feb 2025, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 feb 2025, 21:01 UTC

Ganancias

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 ene 2025, 09:59 UTC

Acciones populares

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 nov 2024, 22:21 UTC

Ganancias

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 nov 2024, 21:25 UTC

Ganancias

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 nov 2024, 21:03 UTC

Ganancias

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

Comparación entre iguales

Cambio de precio

Vertex Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

14.74% repunte

Estimación a 12 meses

Media 516.89 USD  14.74%

Máximo 621 USD

Mínimo 423 USD

De acuerdo con 26 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

26 ratings

13

Comprar

13

Mantener

0

Vender

Puntuación técnica

By Trading Central

428.545 / 498.65Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

120 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.